On Monday, Shares of Allergan PLC (NYSE:AGN), lost -0.31% to $298.71.
Allergan plc, declared the 6-month interim results from a 24-month Phase I/II clinical trial of 75 patients, which showed that a single dose of Bimatoprost Sustained-Release (SR) lowered intraocular pressure (IOP) in 92 percent (n= 69) of glaucoma patients at 4 months and 71 percent (n=53) at 6 months while demonstrating a favorable efficacy and safety profile. Bimatoprost SR is a biodegradable, intracameral implant providing slow release of bimatoprost and is a differentiated approach to treat glaucoma beyond conventional daily eye drop treatments because it is a non-daily treatment administered by a physician.
“We are encouraged by these interim results, and Phase III trials are presently underway,” said David Nicholson, Ph.D., Executive Vice President and President, Global Brands Research & Development, Allergan. “Bimatoprost SR has the potential to be a novel approach to treat glaucoma beyond conventional eye drop treatments and illustrates our commitment to bringing innovative solutions for physicians to assist them meet the needs of their patients.”
In the Phase I/II dose-ranging, paired-eye controlled clinical trial, a total of 75 patients received the implant via an intracameral injection in one eye, and daily topical bimatoprost 0.03% in the other eye. The dose strengths of Bimatoprost SR were 6, 10, 15, or 20 micrograms. All dose strengths of Bimatoprost SR were comparable with topical bimatoprost 0.03% in overall IOP reduction through week 16. The overall mean IOP reduction from baseline at 4 months in study eyes that received a single Bimatoprost SR implant ranged from 7.2 to 9.5 mm Hg while pooled fellow eyes receiving once-daily treatment with topical bimatoprost 0.03% had a reduction of 8.4 mm Hg. At month 6, 71 percent (n=53) of study eyes still had not received topical IOP-lowering rescue or a second injection of Bimatoprost SR.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands.
Shares of NCR Corporation (NYSE:NCR), inclined 2.16% to $26.99, during its last trading session.
First Data (FDC), a global leader in commerce-enabling technology and solutions, and NCR Corporation (NCR), have reached a planned commercial agreement. First Data will be a preferred provider of cyber security and payment processing solutions to NCR’s customers in the grocery, petroleum and convenience store industries. NCR will be a preferred provider of ATM hardware and services to First Data’s client base of more than 4,000 financial institutions. The two industry leaders will also pursue co-development of integrated commerce technology solutions for U.S. merchant clients.
“As respective leaders in payments and consumer transaction technologies across multiple industries, First Data and NCR are uniquely positioned to add customer value through a holistic consumer experience from the initiation of a transaction to its completion,” said Bill Nuti, Chairman and CEO, NCR Corporation. “We believe this new relationship will assist drive revenue growth, reduce costs, and improve security for our customers. As payment security continues to drive decision-making among CIOs and CTOs, NCR and First Data’s unique payment security software will create a winning combination for retailers.”
NCR Corporation, a technology company, provides solutions and services that enable businesses to connect, interact, and transact with their customers worldwide. The company operates through four segments: Financial Services, Retail Solutions, Hospitality, and Emerging Industries.
Finally, Shares of Ally Financial Inc (NYSE:ALLY), ended its last trade with 1.35% gain, and closed at $20.27.
Ally Financial, a leading automotive financial services company, and local auto dealer Classic Chevrolet of Grapevine, TX, presented more than $180,000 in donations to ten local charities in the Dallas area recently.
The generous donations resulted from a special auction held by Ally’s Smart Auction platform to celebrate its 5 millionth vehicle sale. To celebrate the milestone, Ally auctioned off the 5 millionth vehicle, with proceeds promised to the auction winner’s selected charities. Classic Chevrolet of Grapevine, TX won the vehicle with a bid of about $180,000 and selected ten local organizations to receive the money.
“It’s great to be able to celebrate such an important milestone by giving back to a dealer that uses SmartAuction to buy and sell vehicles,” said Steve Kapusta, vice president of dealership online services and remarketing at Ally. “Tom Durant of Classic Chevrolet is an outstanding member of the community, supporting many local charitable organizations, so it is our honor to support his efforts with these grants.”
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers.